POM-V
Prescription Required
Companion Animal
Buproxan Multidose 0.3 mg/ml Solution for Injection for Dogs, Cats and Horses
Active ingredient: Buprenorphine
Form
Injection
Species
Cats
Dogs
Horses
Manufacturer
Alfasan Nederland B.V.
VMD MA No.
36408/3062
What it's used for
Potentiation of the sedative effects of centrally-acting agents. Cats: Post-operative analgesia. Horses: Post-operative analgesia in combination with a sed...
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Buprenorphine
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Clinical information
Buproxan Multidose 0.3 mg/ml Solution for Injection for Dogs, Cats and Horses — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
Potentiation of the sedative effects of centrally-acting agents.
Cats:
Post-operative analgesia.
Horses:
Post-operative analgesia in combination with a sedative.
Potentiation of the sedative effects of centrally-acting agents.
Cats:
Post-operative analgesia.
Horses:
Post-operative analgesia in combination with a sedative.
Potentiation of the sedative effects of centrally-acting agents.
Horses: Intravenous use
Target
species
Route of
administration
Post-operative AnalgesiaPotentiation of
sedation
DogIntramuscular or
intravenous
injection
10-20 equivalent
to 0.3 to 0.6 ml per 10 kg.
For further pain relief,
repeat if necessary after:
-
μg/kg or
-
μg/kg.
10-20
equivalent to 0.3 to 0.6
ml per 10 kg.
CatIntramuscular or
intravenous
injection
10-20 equivalent
to 0.03 to 0.06 ml per 1
kg.
For further pain relief,
repeat if necessary:
-
hours
-HorseIntravenous
injection
10 μg/kg*, equivalent to
3.3 ml per 100 kg, 5
minutes after
administration of an IV
sedative.
For further pain relief,
repeat if necessary:
once, after not less than
1 - 2 hours.
5 μg/kg*, equivalent to
1.7 ml per 100 kg, 5
minutes after
administration of an IV
sedative. The dose
may be repeated if
necessary after 10
minutes
*) The dosages expressed in
in the table refers to body weight
In dogs, sedative effects are present by 15 minutes after administration. In dogs, cats
and horses analgesic activity may not develop fully until 30 minutes. To ensure that
analgesia is present during surgery and immediately on recovery, the product should
be administered preoperatively as part of premedication.
When used in horses, an intravenous sedative should be administered within five
minutes prior to injection of buprenorphine.
When administered for potentiation of sedation or as part of premedication, the dose
of other centrally-acting agents, such as acepromazine or medetomidine, should be
reduced. The reduction will depend on the degree of sedation required, the individual
animal, the type of other agents included in premedication and how anaesthesia is to
be induced and maintained. It may also be possible to reduce the amount of
inhalational anaesthetic used.
Animals administered opioids possessing sedative and analgesic properties may
show variable responses. Therefore, the response of individual animals should be
monitored and subsequent doses should be adjusted accordingly. In some cases,
repeat doses may fail to provide additional analgesia. In these cases, consideration
should be given to using a suitable injectable NSAID.
Due to the small volume to be administered, especially in small dogs and cats, extra
care should be taken to use an appropriately graduated syringe to allow accurate
dosing.
The stopper can be safely punctured up to 25 times.
Target
species
Route of
administration
Post-operative AnalgesiaPotentiation of
sedation
DogIntramuscular or
intravenous
injection
10-20 equivalent
to 0.3 to 0.6 ml per 10 kg.
For further pain relief,
repeat if necessary after:
-
μg/kg or
-
μg/kg.
10-20
equivalent to 0.3 to 0.6
ml per 10 kg.
CatIntramuscular or
intravenous
injection
10-20 equivalent
to 0.03 to 0.06 ml per 1
kg.
For further pain relief,
repeat if necessary:
-
hours
-HorseIntravenous
injection
10 μg/kg*, equivalent to
3.3 ml per 100 kg, 5
minutes after
administration of an IV
sedative.
For further pain relief,
repeat if necessary:
once, after not less than
1 - 2 hours.
5 μg/kg*, equivalent to
1.7 ml per 100 kg, 5
minutes after
administration of an IV
sedative. The dose
may be repeated if
necessary after 10
minutes
*) The dosages expressed in
in the table refers to body weight
In dogs, sedative effects are present by 15 minutes after administration. In dogs, cats
and horses analgesic activity may not develop fully until 30 minutes. To ensure that
analgesia is present during surgery and immediately on recovery, the product should
be administered preoperatively as part of premedication.
When used in horses, an intravenous sedative should be administered within five
minutes prior to injection of buprenorphine.
When administered for potentiation of sedation or as part of premedication, the dose
of other centrally-acting agents, such as acepromazine or medetomidine, should be
reduced. The reduction will depend on the degree of sedation required, the individual
animal, the type of other agents included in premedication and how anaesthesia is to
be induced and maintained. It may also be possible to reduce the amount of
inhalational anaesthetic used.
Animals administered opioids possessing sedative and analgesic properties may
show variable responses. Therefore, the response of individual animals should be
monitored and subsequent doses should be adjusted accordingly. In some cases,
repeat doses may fail to provide additional analgesia. In these cases, consideration
should be given to using a suitable injectable NSAID.
Due to the small volume to be administered, especially in small dogs and cats, extra
care should be taken to use an appropriately graduated syringe to allow accurate
dosing.
The stopper can be safely punctured up to 25 times.
Do not administer by the intrathecal or peridural route.
Do not use pre-operatively for Caesarean section (see Section 3.7).
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use pre-operatively for Caesarean section (see Section 3.7).
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Dogs:
Rare
(1 to 10 animals / 10000 animals
treated):
Hypertension, Tachycardia,
Sedation
.
Very rare
(<1 animal / 10000 animals
treated, including isolated reports):
Injection site pain, Discomfort
,
Vocalisation
.
Undetermined frequency
(cannot be estimated from
available data)
Increased salivation,
Bradycardia,
Hypothermia, Dehydration,
Agitation,
Miosis,
Respiratory depression.
when used to provide analgesia.
local
resulting from injection site pain or local discomfort
Cats:
Common
(1 to 10 animals / 100 animals
treated):
Mydriasis
,
Euphoria (excessive purring, pacing, rubbing)
.
Rare
(1 to 10 animals / 10000 animals
treated):
Sedation
.Very rare
(<1 animal / 10000 animals
treated, including isolated reports):
Injection site pain, Discomfort
,
Vocalisation
.
Undetermined frequency
(cannot be estimated from
available data)
Respiratory depression.
usually resolve within 24 hours.
when used to provide analgesia.
local
resulting from injection site pain or local discomfort.
Horses:
Rare
(1 to 10 animals / 10000 animals
treated):
Sedation
,
Colic.
Undetermined frequency
(cannot be estimated from
available data)
Respiratory depression,
Excitation
,
Ataxia
.
when used to provide analgesia.
when used in conjunction with sedatives or tranquillisers, excitation is normally
minimal, but ataxia may occasionally be marked.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Rare
(1 to 10 animals / 10000 animals
treated):
Hypertension, Tachycardia,
Sedation
.
Very rare
(<1 animal / 10000 animals
treated, including isolated reports):
Injection site pain, Discomfort
,
Vocalisation
.
Undetermined frequency
(cannot be estimated from
available data)
Increased salivation,
Bradycardia,
Hypothermia, Dehydration,
Agitation,
Miosis,
Respiratory depression.
when used to provide analgesia.
local
resulting from injection site pain or local discomfort
Cats:
Common
(1 to 10 animals / 100 animals
treated):
Mydriasis
,
Euphoria (excessive purring, pacing, rubbing)
.
Rare
(1 to 10 animals / 10000 animals
treated):
Sedation
.Very rare
(<1 animal / 10000 animals
treated, including isolated reports):
Injection site pain, Discomfort
,
Vocalisation
.
Undetermined frequency
(cannot be estimated from
available data)
Respiratory depression.
usually resolve within 24 hours.
when used to provide analgesia.
local
resulting from injection site pain or local discomfort.
Horses:
Rare
(1 to 10 animals / 10000 animals
treated):
Sedation
,
Colic.
Undetermined frequency
(cannot be estimated from
available data)
Respiratory depression,
Excitation
,
Ataxia
.
when used to provide analgesia.
when used in conjunction with sedatives or tranquillisers, excitation is normally
minimal, but ataxia may occasionally be marked.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Not applicable.
Special precautions for safe use in the target species:
Buprenorphine should be used with caution in animals with impaired liver function,
especially biliary tract disease, as the substance is metabolised by the liver and its
intensity and duration of action may be affected in such animals.
Buprenorphine may cause respiratory depression and as with other opioid drugs,
care should be taken when treating animals with impaired respiratory function or
animals that are receiving drugs that can cause respiratory depression.
In case of renal, cardiac or hepatic dysfunction or shock, there may be greater risk
associated with the use of the veterinary medicinal product. The benefit-risk
assessment for using the veterinary medicinal product should be made by the
responsible veterinarian. Safety has not been fully evaluated in clinically
compromised cats.
The safety of buprenorphine has not been demonstrated in dogs and cats less than 7
weeks of age, and in horses younger than 10 months old and weighing less than
150kg; therefore, use in such animals should be based on the risk-benefit
assessment of the veterinarian.
Repeat administration earlier than the recommended repeat interval suggested in
section 3.9 is not recommended.
Long-term safety of buprenorphine has not been investigated beyond 5 consecutive
days of administration in cats or 4 separate administrations on 3 consecutive days in
horses.
The effect of an opioid on head injury is dependent on the type and severity of the
injury and the respiratory support supplied. The veterinary medicinal product should
be used in accordance with the benefit-risk assessment of the attending veterinarian.
Safety has not been evaluated in clinically-compromised horses. In horses, use of
opioids has been associated with excitation, but effects with buprenorphine are
minimal when administered in conjunction with sedatives and tranquilisers such as
detomidine, romifidine, xylazine and acepromazine.
Ataxia is a known effect of detomidine and similar agents; consequently it may be
seen after administration of buprenorphine with such substances.
Occasionally, ataxia may be marked. To ensure ataxic horses sedated with
detomidine/buprenorphine do not lose their balance, they should not be moved or
otherwise handled in any way that would compromise their stability.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
As buprenorphine has opioid-like activity, care should be taken to avoid self-injection.
Buprenorphine may be absorbed systemically on accidental exposure to mucous
membranes.The product, which is slightly acidic, may cause skin or eye irritation if
contact occurs. Following eye, skin or mouth contact, wash the affected area
thoroughly with water. Seek medical advice if irritation persists. In case of accidental
self-injection, seek medical advice immediately and show the package leaflet or the
label to the physician.Wash hands after use.
Buprenorphine and the excipient chlorocresol can cause hypersensitivity (allergic)
reactions after skin contact. People with known hypersensitivity to buprenorphine or
chlorocresol should avoid contact with the veterinary medicinal product. In case of
accidental skin contact, wash off immediately with water.
To the physician: In case of accidental self-injection the opioid antagonist naloxone
may be used as antidote.
Special precautions for the protection of the environment:
Not applicable.
Special precautions for safe use in the target species:
Buprenorphine should be used with caution in animals with impaired liver function,
especially biliary tract disease, as the substance is metabolised by the liver and its
intensity and duration of action may be affected in such animals.
Buprenorphine may cause respiratory depression and as with other opioid drugs,
care should be taken when treating animals with impaired respiratory function or
animals that are receiving drugs that can cause respiratory depression.
In case of renal, cardiac or hepatic dysfunction or shock, there may be greater risk
associated with the use of the veterinary medicinal product. The benefit-risk
assessment for using the veterinary medicinal product should be made by the
responsible veterinarian. Safety has not been fully evaluated in clinically
compromised cats.
The safety of buprenorphine has not been demonstrated in dogs and cats less than 7
weeks of age, and in horses younger than 10 months old and weighing less than
150kg; therefore, use in such animals should be based on the risk-benefit
assessment of the veterinarian.
Repeat administration earlier than the recommended repeat interval suggested in
section 3.9 is not recommended.
Long-term safety of buprenorphine has not been investigated beyond 5 consecutive
days of administration in cats or 4 separate administrations on 3 consecutive days in
horses.
The effect of an opioid on head injury is dependent on the type and severity of the
injury and the respiratory support supplied. The veterinary medicinal product should
be used in accordance with the benefit-risk assessment of the attending veterinarian.
Safety has not been evaluated in clinically-compromised horses. In horses, use of
opioids has been associated with excitation, but effects with buprenorphine are
minimal when administered in conjunction with sedatives and tranquilisers such as
detomidine, romifidine, xylazine and acepromazine.
Ataxia is a known effect of detomidine and similar agents; consequently it may be
seen after administration of buprenorphine with such substances.
Occasionally, ataxia may be marked. To ensure ataxic horses sedated with
detomidine/buprenorphine do not lose their balance, they should not be moved or
otherwise handled in any way that would compromise their stability.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
As buprenorphine has opioid-like activity, care should be taken to avoid self-injection.
Buprenorphine may be absorbed systemically on accidental exposure to mucous
membranes.The product, which is slightly acidic, may cause skin or eye irritation if
contact occurs. Following eye, skin or mouth contact, wash the affected area
thoroughly with water. Seek medical advice if irritation persists. In case of accidental
self-injection, seek medical advice immediately and show the package leaflet or the
label to the physician.Wash hands after use.
Buprenorphine and the excipient chlorocresol can cause hypersensitivity (allergic)
reactions after skin contact. People with known hypersensitivity to buprenorphine or
chlorocresol should avoid contact with the veterinary medicinal product. In case of
accidental skin contact, wash off immediately with water.
To the physician: In case of accidental self-injection the opioid antagonist naloxone
may be used as antidote.
Special precautions for the protection of the environment:
Not applicable.
Buprenorphine may cause some drowsiness, which may be potentiated by other
centrally acting agents, including tranquillisers, sedatives and hypnotics.
There is evidence in humans to indicate that therapeutic doses of buprenorphine do
not reduce the analgesic efficacy of standard doses of an opioid agonist, and that
when buprenorphine is employed within the normal therapeutic range, standard
doses of opioid agonist may be administered before the effects of the former have
ended without compromising analgesia. However, it is recommended that
buprenorphine is not used in conjunction with morphine or other opioid-type
analgesics, e.g. etorphine, fentanyl, pethidine, methadone, papaveretum or
butorphanol.
Buprenorphine has been used with acepromazine, alphaxalone/alphadalone,
atropine, detomidine, dexmedetomidine, halothane, isoflurane, ketamine,
medetomidine, propofol, romifidine, sevoflurane, thiopentone and xylazine. When
used in combination with sedatives, depressive effects on heart rate and respiration
may be augmented.
centrally acting agents, including tranquillisers, sedatives and hypnotics.
There is evidence in humans to indicate that therapeutic doses of buprenorphine do
not reduce the analgesic efficacy of standard doses of an opioid agonist, and that
when buprenorphine is employed within the normal therapeutic range, standard
doses of opioid agonist may be administered before the effects of the former have
ended without compromising analgesia. However, it is recommended that
buprenorphine is not used in conjunction with morphine or other opioid-type
analgesics, e.g. etorphine, fentanyl, pethidine, methadone, papaveretum or
butorphanol.
Buprenorphine has been used with acepromazine, alphaxalone/alphadalone,
atropine, detomidine, dexmedetomidine, halothane, isoflurane, ketamine,
medetomidine, propofol, romifidine, sevoflurane, thiopentone and xylazine. When
used in combination with sedatives, depressive effects on heart rate and respiration
may be augmented.
This veterinary medicinal product does not require any special storage conditions.
Not authorised for use in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under
national horse passport legislation.
Not authorised for use in animals producing milk for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under
national horse passport legislation.
Not authorised for use in animals producing milk for human consumption.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Same active ingredient
Other Products Containing Buprenorphine
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Bupaq 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VVetViva Richter GmbH
injection
Cats
Dogs
Bupaq Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VVetViva Richter GmbH
injection
Cats
Dogs
Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VEcuphar NV
injection
Cats
Dogs
Buprecare Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VEcuphar NV
injection
Cats
Dogs
Buprecord 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VLabiana Life Sciences SA
injection
Cats
Dogs
Buprecord 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VLabiana Life Sciences SA
injection
Cats
Dogs
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Save up to 50%
Shop now
Pharmacy2U
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
Free delivery £30+
Shop now
Petlibro
Petlibro Automatic Feeder
Smart automatic pet feeder with app control. Schedule meals, portion control, and feeding history.
From £49.99
Shop now
We may earn a small commission if you purchase through these links, at no extra cost to you.
Also in painkiller
Related Medications
Alvegesic Vet. 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VButorphanol
injection
Rx
Cats
Dogs
Alvegesic Vet. 10 mg/ml Solution for Injection for Horses, Dogs and Cats
POM-VButorphanol
injection
Rx
Cats
Dogs
Bupaq 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
injection
Rx
Cats
Dogs
Bupaq Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
injection
Rx
Cats
Dogs
Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
injection
Rx
Cats
Dogs
Buprecare Multidose 0.3 mg/ml Solution for Injection for Dogs and Cats
POM-VBuprenorphine
injection
Rx
Cats
Dogs
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.